Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep 15;6:249. doi: 10.3389/fphys.2015.00249

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Xing, Lu and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Changes in MAP, HR and muscle tension in response to static contraction after an inhibition of TRPA1 by 3 mg of HC-030031 (TRPA1 antagonist). Muscle contraction was evoked by electrical stimulation of the L4 and L5 ventral roots. Blocking TRPA1 significantly attenuated the MAP and HR responses to muscle contraction in control rats and rats with 24 h of femoral artery ligation. (A,B) Typical traces obtained from a control rat and ligated rat. (C) Average data. The attenuating effects of HC-030031 were greater in ligated rats (MAP and HR: 59 and 67%. P < 0.05 vs. control rats, n = 8) than in control rats (MAP and HR: 38 and 49%, n = 8). No significant difference was observed in baseline MAP and HR, and muscle tension responses in two groups. Values are means ± SEM. ^*P < 0.05 vs. vehicle control. ^†P < 0.05 indicates ligated rats vs. control rats.